Glycolic acid/lactic acid copolymer obtained by open-loop recombination.
The "Glycolic Acid/Lactic Acid Copolymer (PGDLLA)" is obtained by using glycoride (the cyclic dimer of glycolic acid) and lactide (the cyclic dimer of lactic acid) as monomers and performing ring-opening polymerization of these compounds. Lactide can be classified into three types (L-lactide, D-lactide, and DL-lactide) due to its optical activity, so we refer to the copolymer of glycoride and DL-lactide as "PGDLLA." Our BioDegmer is produced in facilities compliant with ISO 13485, can be processed into a wide variety of shapes, and is used in a broad range of applications in the medical field. 【Features】 ■ Obtained through ring-opening polymerization ■ Flexible processing characteristics ■ Capable of being processed into various shapes ■ Properties: Insoluble (high glycoride content) *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Specifications (Example)】 Test Items: Standards ■ Polymer Identification: Must match the NMR spectrum of standard PGDLLA ■ Composition: CGA:CLA = 20:80 − 30:70 (mol%) ■ Molecular Weight (MW): MW = 220,000 − 280,000 ■ Glass Transition Temperature (Tg): Tg = 50 − 60 (℃) ■ Particle Size: Must not pass through a sieve with an opening of 500 µm * This is the specification (standard) for our representative PGDLLA polymer (PGDLLA(25:75)). * For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Uses】 ■Membrane: periodontal tissue regeneration membrane, artificial dura mater, adhesion prevention membrane, scaffold *For more details, please refer to the PDF document or feel free to contact us.
catalog（2）
Download All Catalogs
Company information
BMG is a research and development venture company that has been challenging the development of new biomaterial products adapted to trends in the medical field, based on a long-standing strong collaboration with the Kyoto University Institute for Advanced Medical Research. Focusing on the field of medical polymers (macromolecules), we are engaged in two promising growth businesses: the "BioDegmer" business and the new products business, as well as research and development aimed at providing innovative solutions in the medical field. Under the management philosophy of "contributing to the health of people around the world by working on the development of better biomaterial products and providing innovative solutions in the medical field," we support the improvement of technologies in the next generation of regenerative medicine and the healthy well-being of people in three areas.